PharMerica Co. (NYSE:PMC) CEO Sells $15,241,853.25 in Stock

PharMerica Co. (NYSE:PMC) CEO Gregory S. Weishar sold 521,089 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $29.25, for a total transaction of $15,241,853.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

PharMerica Co. (NYSE:PMC) traded up $0.05 during midday trading on Friday, reaching $29.25. 1,371,600 shares of the company’s stock traded hands, compared to its average volume of 283,015. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.58 and a quick ratio of 1.79. The stock has a market capitalization of $910.27, a price-to-earnings ratio of 47.95, a price-to-earnings-growth ratio of 1.27 and a beta of 0.82. PharMerica Co. has a 52 week low of $22.00 and a 52 week high of $29.50.

PharMerica (NYSE:PMC) last posted its quarterly earnings data on Thursday, November 9th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $596.80 million. PharMerica had a return on equity of 2.30% and a net margin of 0.54%. research analysts anticipate that PharMerica Co. will post 1.92 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allianz Asset Management GmbH lifted its position in shares of PharMerica by 3,347.4% during the third quarter. Allianz Asset Management GmbH now owns 399,591 shares of the company’s stock worth $11,708,000 after purchasing an additional 388,000 shares during the last quarter. Royce & Associates LP lifted its position in shares of PharMerica by 966.5% during the second quarter. Royce & Associates LP now owns 426,600 shares of the company’s stock worth $11,198,000 after purchasing an additional 386,600 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of PharMerica by 40.1% during the second quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock worth $33,971,000 after purchasing an additional 370,266 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of PharMerica by 3,799.6% during the third quarter. SG Americas Securities LLC now owns 281,007 shares of the company’s stock worth $8,234,000 after purchasing an additional 273,801 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of PharMerica during the third quarter worth $7,031,000. 89.97% of the stock is owned by institutional investors.

A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of PharMerica from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. ValuEngine lowered shares of PharMerica from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $30.50.

TRADEMARK VIOLATION NOTICE: “PharMerica Co. (NYSE:PMC) CEO Sells $15,241,853.25 in Stock” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/01/05/pharmerica-co-pmc-ceo-sells-15241853-25-in-stock-updated-updated-updated.html.

PharMerica Company Profile

Insider Buying and Selling by Quarter for PharMerica (NYSE:PMC)

Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply